These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25602530)

  • 41. The PCSK9 decade.
    Lambert G; Sjouke B; Choque B; Kastelein JJ; Hovingh GK
    J Lipid Res; 2012 Dec; 53(12):2515-24. PubMed ID: 22811413
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.
    Cai G; Zhang B; Shi G; Weng W; Ma C; Song Y; Zhang J
    Lipids Health Dis; 2015 Nov; 14():149. PubMed ID: 26576960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy.
    Berge KE; Ose L; Leren TP
    Arterioscler Thromb Vasc Biol; 2006 May; 26(5):1094-100. PubMed ID: 16424354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels.
    Abujrad H; Mayne J; Ruzicka M; Cousins M; Raymond A; Cheesman J; Taljaard M; Sorisky A; Burns K; Ooi TC
    Atherosclerosis; 2014 Mar; 233(1):123-9. PubMed ID: 24529132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
    Lopez D
    Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations.
    Aung LH; Yin RX; Miao L; Hu XJ; Yan TT; Cao XL; Wu DF; Li Q; Pan SL; Wu JZ
    Lipids Health Dis; 2011 Jan; 10():5. PubMed ID: 21232153
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circulating Mature PCSK9 Level Predicts Diminished Response to Statin Therapy.
    Kuyama N; Kataoka Y; Takegami M; Nishimura K; Harada-Shiba M; Hori M; Ogura M; Otsuka F; Asaumi Y; Noguchi T; Tsujita K; Yasuda S
    J Am Heart Assoc; 2021 Jun; 10(11):e019525. PubMed ID: 33998287
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.
    Dong B; Wu M; Li H; Kraemer FB; Adeli K; Seidah NG; Park SW; Liu J
    J Lipid Res; 2010 Jun; 51(6):1486-95. PubMed ID: 20048381
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease.
    Nozue T; Hattori H; Ishihara M; Iwasaki T; Hirano T; Kawashiri MA; Yamagishi M; Michishita I
    Am J Cardiol; 2013 May; 111(10):1415-9. PubMed ID: 23433768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe.
    Fazio S
    Atheroscler Suppl; 2015 Feb; 17():23-6. PubMed ID: 25659873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).
    Ferdinand KC; Nasser SA
    Cardiovasc Drugs Ther; 2015 Jun; 29(3):295-308. PubMed ID: 26068408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men.
    Gouni-Berthold I; Berthold HK; Gylling H; Hallikainen M; Giannakidou E; Stier S; Ko Y; Patel D; Soutar AK; Seedorf U; Mantzoros CS; Plat J; Krone W
    Atherosclerosis; 2008 May; 198(1):198-207. PubMed ID: 17980884
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
    Scartezini M; Hubbart C; Whittall RA; Cooper JA; Neil AH; Humphries SE
    Clin Sci (Lond); 2007 Dec; 113(11):435-41. PubMed ID: 17550346
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients.
    Chan DC; Hamilton SJ; Rye KA; Chew GT; Jenkins AJ; Lambert G; Watts GF
    Diabetes Obes Metab; 2010 Sep; 12(9):752-6. PubMed ID: 20649626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
    Paton DM
    Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.
    Davignon J; Dubuc G
    Trans Am Clin Climatol Assoc; 2009; 120():163-73. PubMed ID: 19768174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.